RESUMENActualmente existe un intenso debate sobre los beneficios de ofrecer las pruebas de cribado de cáncer de mama (PCCM) a todas las mujeres a partir de los 50 años, ya que no está claro que sean superiores a sus riesgos. Asimismo, la percepción pública no es realista. Las participantes sobreestiman los beneficios y están ajenas del impacto físico o psicológico negativo del sobrediagnóstico y de los falsos positivos. Además, no hay una estrategia clara para facilitar que tomen decisiones informadas acerca de su participación en la prueba. En este contexto, se llevó a cabo un proceso de Democracia Deliberativa (DD) en Cádiz (España) con el doble objetivo de conocer la opinión de las participantes sobre la información recibida acerca del PCCM; y saber qué estrategias consideran que mejorarían el proceso de recepción de información que facilitaría la toma de decisiones informada.Participaron trece mujeres de 50 a 65 años. El proceso de DD se llevó a cabo durante tres tardes: se suministró información sobre el cribado mamográfico; se dieron argumentos a favor y en contra del PCCM; las participantes deliberaron sobre la información suministrada, y propusieron cambios en la información que reciben.Las participantes expresaron su opinión sobre la información que reciben del PCCM en cuanto a sus objetivos, las fuentes de información y las destinatarias, la claridad de la misma, y cuándo y cómo la reciben. Asimismo, indicaron cómo les gustaría recibir información sobre la PCCM-canal de llegada de la misma-, el momento, los contenidos sobre los que les gustaría estar informadas, personas destinatarias y protocolo de actuación.Se concluye que es necesario conocer el punto de vista de las participantes en el PCCM para mejorar la información que reciben, adaptarla a sus necesidades y que puedan llevar a cabo una toma de decisiones informada sobre su participación.Palabras clave: cribado mamográfico; democracia deliberativa; calidad de la información; toma de decisiones informada ABSTRACTMammography screening test: how users receive information and how they want to be informed. There is currently intense international debate about the benefits of offering breast cancer screening tests (BCST) to all women aged 50 and older, as it is not clear that they outweigh the risks. Also, public perception is unrealistic. Participants overestimate the benefits and are oblivious to the negative physical or psychological impact of overdiagnosis and false positives. In addition, there is no clear strategy to make easier for them to make informed decisions about their participation in the test. In this context, a deliberative democracy (DD) process was carried out in Cadiz (Spain) with the dual objective of knowing the opinion of the participants on the PCCM; and knowing which strategies they consider would improve the information reception process and facilitate informed decision making.Participated thirteen women between the ages of 50 and 65. The DD process took place over three afternoons: (1) information on mammographic screening was ...
Background: Pertuzumab (P) has been aproved in neoadjuvant setting for HER2 positive early breasta cancer patients in association with Trastuzumab (T) and chemotherapy. Diverse studies support this combination as NeoSphere, Tryphaena, GeparSepto or Berenice trial. Some of these studies combine P - T with taxanes and sequencing anthracyclines, and other use antraciclines-free regimen as Carboplatine-Docetaxel-P-T. The patologic complete response (pCR) showed achieve percentages from 45.8 % to 66.6% depending on chemotherapy combination. In Spain, the approval of new drugs is a national issue, but sometimes regional regulatory agencies could modify some indications. We have carry out this study in routine patients as our daily clinical practice. Aims: This is a retrospective and multicentric study that has investigated the clinical characteristics, treatment patterns, safety and clinical outcomes for patient with HER-2 positive early breast cancer patients. Methods: We have collected all HER2 positive early breast cancer patients treated with P in neoadjuvant setting in our hospitals. The effect of adding Pertuzumab on pCR was analyzed, as well as other predictive factors of response using logistic regression analyses. Results: A total of 298 patients met the selection criteria. The median age was 50 years (range 24-88 years), 54,2% were premenopausic. 4 patients were stage I, 194 patients stage II, 95 patients were stage III and one patient was stage IV. 76,3% of the patient had a ki67 >20%. The majority of the patient received anthracyclines and taxanes with P and T regimen (80,7%), 13,2% received carboplatin-docetaxel-P-T combination and only 6,1% received taxane-P-T. 292 patients were analysed for response. pCR was seen in 61,7 % of the patients, dividing by hormonal receptor (HR) status, pCR was 53,29% in HR-positive and 72,14% in HR-negative. 63,4% of the patients received breast conservative surgery. Grade 3-4 chemo-related toxicity was presented in 14,2% of patients, 3 patients presented cardiac toxicity. Different treatments patterns were seen between hospitals: only 15 patients (5,1%) complete adjuvant Pertuzumab, 4 patients (1,4%) received adjuvant Neratinib and 2 patients (0,7%) received adjuvant TDM1. Only 12 patients (4,1%) has presented a distant recurrence, 6 of them (50%) had achieved a previous pCR. Conclusion: In our knowledge, this is the biggest real-world-data presented until this year, for Pertuzumab in the neoadjuvant setting of HER2 positive breast cancer patients. Our results are consistent with those published in previous clinical trial. pCR by subtypepCR NOpCR YESTotalLuminal B HER2+7181152HER2+39101140Total110182292 Citation Format: Alejandro Falcón González, Rocío Álvarez Ambite, Elisenda Llabrés Valenti, Rocío Urbano Cubero, Maria del Carmen Álamo de la Gala, Antonia Martínez Guisado, Carlos José Rodríguez González, Marta Amérigo Góngora, Encarnación González Flores, Salvador Gámez Casado, María Valero Arbizu, Alicia Quilez Cutillas, Josefina Cruz Jurado, Pedro Sánchez Rovira, Fernando Henao Carrasco, Javier Salvador Bofill, Manuel Ruiz Borrego. Neopersur: Neoadjuvant pertuzumab in a real world data population in the south of Spain [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-18-29.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.